Understand the source comparison
Peptides for Chronic Pain: Therapeutic Peptide Comparison
Before selecting a peptide for research or clinical investigation, understanding the mechanism, receptor target, and evidence base is essential. This table compares the most-studied analgesic peptides across key parameters. BPC-157 Tissue repair, angiogenesis,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide for research or clinical investigation, understanding the mechanism, receptor target, and evidence base is essential. This table compares the most-studied analgesic peptides across key parameters.
- BPC-157
- Tissue repair, angiogenesis, anti-inflammatory signaling
- Growth factor pathways, VEGF upregulation
- Preclinical (rodent models), Phase I human trials underway
- Minimal. No respiratory depression, no GI toxicity reported in studies to date
- Best evidence for inflammatory and musculoskeletal pain; acts upstream of nociception by resolving tissue damage
- Endomorphin-2
- Mu-opioid receptor agonism (highly selective)
- Mu-opioid receptors (MOR)
- Preclinical (rodent thermal/mechanical pain models)
- Lower constipation and respiratory depression vs morphine; tolerance unclear in chronic dosing
- Strong analgesic efficacy without beta-arrestin recruitment; tolerance risk requires long-term study
- Thymosin Beta-4
- Wound healing, cytokine modulation, actin regulation
- Not receptor-mediated. Intracellular signaling
- Preclinical and early clinical (cardiac/wound healing contexts)
- Minimal. Well-tolerated in published studies
- Indirect analgesic effect through accelerated resolution of underlying pathology
- KPV
- NF-kB inhibition, anti-inflammatory gene suppression
- Intracellular (blocks inflammatory transcription factors)
- Preclinical (colitis, inflammatory models)
- Minimal systemic effects; localized administration preferred
- Mechanistically sound for inflammatory pain; human chronic pain data limited
- Deltorphin
- Delta-opioid receptor agonism (selective)
- Delta-opioid receptors (DOR)
- Preclinical (neuropathic pain models)
- Less respiratory depression than mu agonists; some GI effects
- Effective for neuropathic and peripheral pain; spinal/intrathecal administration limits clinical utility
- Hemopressin
- CB1 inverse agonist (cannabinoid system modulation)
- Cannabinoid CB1 receptors
- Preclinical (limited studies)
- Non-psychoactive; tolerability unclear
- Theoretical benefit for central sensitization; evidence base too limited for recommendation